Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (451)	2/4/2004 5:00:34 PM
From: tuck	Respond to of 625

From today's Briefing.com: >>2:01PM Abbott Labs initiates Phase III trial to explore use of Humira in AS (ABT) 44.40 +0.15: Co announced today the initiation of a global Phase III study evaluating the potential of HUMIRA in treating ankylosing spondylitis (AS). AS is an autoimmune disorder in which a human protein, tumor necrosis factor-alpha (TNF-a), appears to play a role in the disease development. Data from clinical studies suggest that inhibition of TNF-a may be active against this disease state. HUMIRA, which is a fully human monoclonal antibody that resembles antibodies normally found in the body, works by specifically blocking TNF-a.<< Cheers, Tuck